Aurinia Pharmaceuticals Inc (FRA:IKAP)
€ 8.542 -0.116 (-1.34%) Market Cap: 1.23 Bil Enterprise Value: 978.48 Mil PE Ratio: 0 PB Ratio: 3.30 GF Score: 81/100

Q2 2022 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Aug 04, 2022 / 12:30PM GMT
Release Date Price: €8.11 (+0.45%)
Operator

Greetings, and welcome to Aurinia Pharmaceuticals' Second Quarter 2022 Financial and Operational Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, DeDe Sheel, Aurinia's Vice President of Investor Relations. Thank you. You may begin.

DeDe Sheel
Aurinia Pharmaceuticals Inc. - VP of Investor Relation

Thank you, Doug, and thank you all for joining today's call and webcast to discuss Aurinia's second quarter 2022 financial results. Joining me this morning to lead the call are Peter Greenleaf, President and CEO; and Joe Miller, Chief Financial Officer; Dr. Neil Solomons, Chief Medical Officer, will also be available at the conclusion of our prepared remarks for the Q&A portion of the call.

This morning, we issued a press release announcing our financial results and recent operational highlights and filed our quarterly report on Form 10-Q. For more information, please refer to our filings with the U.S. SEC, which are available on our website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot